Roche and Lilly's Alzheimer's drugs draw blanks in inherited...
As Biogen prepares for an FDA review of its amyloid-targeting Alzheimer’s drug aducanumab, Roche and Eli Lilly lifted the lid on yet another trial failure involving two drugs aimed at this
